Aikaterini Patsatsi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2210727/publications.pdf

Version: 2024-02-01

96 1,663 20 papers citations h-index

361296 360920 35
h-index g-index

100 100 all docs citations

100 times ranked 1956 citing authors

#	Article	IF	CITATIONS
1	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology, 2020, 82, 575-585.e1.	0.6	224
2	The PROCLIPI international registry of earlyâ€stage mycosis fungoides identifies substantial diagnostic delay in most patients. British Journal of Dermatology, 2019, 181, 350-357.	1.4	127
3	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1926-1948.	1.3	86
4	European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1750-1764.	1.3	72
5	Serum Leptin, Resistin, and Adiponectin Concentrations in Psoriasis: A Meta-Analysis of Observational Studies. Dermatology, 2017, 233, 378-389.	0.9	68
6	Netherton Syndrome: A Genotype-Phenotype Review. Molecular Diagnosis and Therapy, 2017, 21, 137-152.	1.6	62
7	International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. British Journal of Dermatology, 2018, 179, 30-41.	1.4	62
8	Serum Levels of TNF- $\langle i \rangle \hat{l}_{\pm} \langle i \rangle$, IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity. Journal of Immunology Research, 2014, 2014, 1-9.	0.9	55
9	Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases. Journal of the American Academy of Dermatology, 2017, 76, 889-894.e5.	0.6	46
10	Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*. British Journal of Dermatology, 2021, 185, 745-755.	1.4	42
11	Treatment of earlyâ€stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*. British Journal of Dermatology, 2021, 184, 722-730.	1.4	39
12	Benign Cephalic Histiocytosis: Case Report and Review of the Literature. Pediatric Dermatology, 2014, 31, 547-550.	0.5	35
13	S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1251-1277.	1.3	34
14	International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cutâ€off values for defining mild, moderate and severe types of bullous pemphigoid*. British Journal of Dermatology, 2021, 184, 1106-1112.	1.4	33
15	Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data. Dermatology Reports, 2018, 10, 7859.	0.4	29
16	Efficacy of microneedling with topical vitamin C in the treatment of melasma. Journal of Cosmetic Dermatology, 2019, 18, 1342-1347.	0.8	28
17	Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. Journal of the American Academy of Dermatology, 2020, 83, 1315-1322.	0.6	28
18	Medication history of a series of patients with bullous pemphigoid from northern Greece - observations and discussion. International Journal of Dermatology, 2009, 48, 132-135.	0.5	26

#	Article	IF	Citations
19	Pemphigus vulgaris affecting 19 nails. Clinical and Experimental Dermatology, 2009, 34, 202-205.	0.6	26
20	Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature. Acta Dermato-Venereologica, 2021, 101, adv00377.	0.6	26
21	Prognostic indicators for mycosis fungoides in a Greek population. British Journal of Dermatology, 2017, 176, 1321-1330.	1.4	25
22	Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis. British Journal of Dermatology, 2018, 179, 273-281.	1.4	23
23	Association of Autoantibodies to BP180 with Disease Activity in Greek Patients with Bullous Pemphigoid. Clinical and Developmental Immunology, 2012, 2012, 1-4.	3.3	22
24	Prevalence of onychomycosis among patients with nail psoriasis who are not receiving immunosuppressive agents: Results of a pilot study. Mycoses, 2017, 60, 830-835.	1.8	20
25	Bullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?. European Journal of Dermatology, 2018, 28, 711-713.	0.3	20
26	A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. Pharmacogenomics Journal, 2014, 14, 523-525.	0.9	19
27	Epidemiology of superficial mycoses in Northern Greece: a 4-year study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 837-839.	1.3	19
28	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus—An Ongoing Need for International Consensus and Collaborations. Journal of Investigative Dermatology, 2019, 139, 270-276.	0.3	18
29	Should we be imaging lymph nodes at initial diagnosis of earlyâ€stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*. British Journal of Dermatology, 2021, 184, 524-531.	1.4	18
30	Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre. European Journal of Dermatology, 2019, 29, 490-499.	0.3	16
31	FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors. Pharmacogenomics Journal, 2017, 17, 237-241.	0.9	13
32	Bullous pemphigoid in adolescence. Pediatric Dermatology, 2019, 36, 184-188.	0.5	13
33	The possible role of oral microbiome in autoimmunity. International Journal of Women's Dermatology, 2020, 6, 357-364.	1.1	13
34	Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicentre study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2534-2540.	1.3	12
35	Serum Levels of TNF- $\langle b \rangle \langle i \rangle$ $\pm \langle i \rangle \langle b \rangle$, IL-12/23 p40, and IL-17 in Psoriatic Patients with and without Nail Psoriasis: A Cross-Sectional Study. Scientific World Journal, The, 2014, 2014, 1-5.	0.8	11
36	Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?. Clinics in Dermatology, 2021, 39, 52-55.	0.8	11

#	Article	IF	CITATIONS
37	Detection of anti-BP180NC16a and anti-BP230 autoantibodies in blister fluid of patients with bullous pemphigoid: the first survey in Greece. Clinical and Experimental Dermatology, 2008, 33, 183-185.	0.6	10
38	Circulating Anti-BP180 NC16a and Anti-BP230 Autoantibodies in Patients with Genital Lichen Sclerosus Do Not Correlate with Disease Activity and Pruritus. Acta Dermato-Venereologica, 2014, 94, 711-712.	0.6	10
39	Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes. Acta Dermato-Venereologica, 2017, 97, 1145-1147.	0.6	10
40	A case of palisaded neutrophilic granulomatous dermatitis with subsequent development of chronic myelomonocytic leukemia. Clinical Case Reports (discontinued), 2019, 7, 695-698.	0.2	10
41	Solitary trichoepithelioma in an 8-year-old child: clinical, dermoscopic and histopathologic findings. Dermatology Practical and Conceptual, 2014, 4, 55-58.	0.5	10
42	Quality of life and severity of skin and nail involvement in patients with plaque psoriasis. European Journal of Dermatology, 2014, 24, 623-625.	0.3	9
43	Interâ€rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2327-2333.	1.3	9
44	Autoimmune bullous diseases during pregnancy: Solving common and uncommon issues. International Journal of Women's Dermatology, 2019, 5, 166-170.	1.1	9
45	Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus. Frontiers in Medicine, 2021, 8, 708071.	1.2	9
46	Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of disease. Journal of Advanced Research, 2023, 44, 71-79.	4.4	9
47	The cellular microenvironment and neoplastic population in mycosis fungoides skin lesions: a clinicopathological correlation. European Journal of Dermatology, 2016, 26, 566-571.	0.3	8
48	Eccrine porocarcinoma of the thumb in a patient with chronic exposure to benzene glue. Journal of Hand and Microsurgery, 2016, 07, 157-160.	0.1	8
49	A Family with Atypical Hailey Hailey Disease- Is There More to the Underlying Genetics than ATP2C1?. PLoS ONE, 2015, 10, e0121253.	1.1	8
50	Protein and mRNA Expression Levels of Interleukin-17A, -17F and -22 in Blood and Skin Samples of Patients with Mycosis Fungoides. Acta Dermato-Venereologica, 2020, 100, adv00326.	0.6	8
51	The agreement among the different ways of measuring NAPSI and their correlation with DLQI. JDDG - Journal of the German Society of Dermatology, 2014, 12, 1051-1053.	0.4	7
52	Atypical Presentation of Sjögren-Larsson Syndrome. Case Reports in Pediatrics, 2017, 2017, 1-4.	0.2	6
53	Head and neck Merkel cell carcinoma: a retrospective case series and critical literature review with emphasis on treatment and prognosis. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018, 125, 126-139.	0.2	6
54	The role of oral microbiome in pemphigus vulgaris. Archives of Microbiology, 2021, 203, 2237-2247.	1.0	6

#	Article	IF	CITATIONS
55	Chlormethine gel is effective for the treatment of skin lesions in patients with early―and lateâ€stage mycosis fungoides in clinical practice. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1751-1757.	1.3	6
56	Bilateral Aleukemic Myeloid Sarcoma of the Eyelids With Indolent Course. American Journal of Dermatopathology, 2016, 38, 312-314.	0.3	5
57	Chronic bullous disease of childhood with IgG reactivity to p200 antigen. International Journal of Dermatology, 2017, 56, 773-775.	0.5	5
58	Multiple milia formation in blistering diseases. International Journal of Women's Dermatology, 2020, 6, 199-202.	1.1	5
59	Fungal Infections and Nail Psoriasis: An Update. Journal of Fungi (Basel, Switzerland), 2022, 8, 154.	1.5	5
60	New onset pemphigus foliaceus during pregnancy: A rare case. International Journal of Women's Dermatology, 2018, 4, 109-112.	1.1	4
61	Association ofNFKB1 â€94ATTGins/del polymorphism (rs28362491) with pemphigus vulgaris. Experimental Dermatology, 2019, 28, 972-975.	1.4	4
62	Diagnostic and management challenges of erosive pustular dermatosis of the scalp: a retrospective study in Greek population. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e776-e779.	1.3	4
63	Effectiveness and safety of apremilast in biologicâ \in na \tilde{A} -ve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1838-1848.	1.3	4
64	Multiple sclerosis is the neurological disorder most highly associated with bullous pemphigoid. British Journal of Dermatology, 2017, 176, 1428-1429.	1.4	4
65	The use of pegylated interferon aâ€2a in a cohort of Greek patients with mycosis fungoides. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	4
66	Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2181-2189.	1.3	4
67	Silent Tâ€cell lymphoma of γδTâ€cell origin initially presented as panniculitis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1244-1245.	1.3	3
68	A comparative study of three extraction protocols of <scp>DNA</scp> from nails: Potential use in the diagnosis of onychomycoses. Mycoses, 2017, 60, 183-187.	1.8	3
69	Mycosis fungoides in patients with psoriasis: an ongoing issue. European Journal of Dermatology, 2018, 28, 235-236.	0.3	3
70	Dermatomyositis in patients with autoimmune blistering diseases. International Journal of Women's Dermatology, 2019, 5, 256-260.	1.1	3
71	Phase 2 <scp>BELIEVE</scp> study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	3
72	Beteiligung der OhrlÄppchen bei chronischer lymphatischer LeukÄmie. JDDG - Journal of the German Society of Dermatology, 2013, 11, 80-82.	0.4	2

#	Article	IF	Citations
73	Management of primary cutaneous lymphomas during the COVID-19 pandemic. Clinics in Dermatology, 2021, 39, 64-75.	0.8	2
74	The impact of COVIDâ€19 pandemic on psoriasis patients in northern Greece. Dermatologic Therapy, 2022, 35, e15244.	0.8	2
75	How Do Experts Treat Patients with BullousÂPemphigoid around the World? AnÂInternational Survey. JID Innovations, 2022, 2, 100129.	1.2	2
76	Sclerotic Regressing Large Congenital Nevus. Pediatric Dermatology, 2016, 33, e366-e367.	0.5	1
77	Efficacy of omalizumab in severe chronic spontaneous urticaria: Real life data from a Greek tertiary center. Dermatologic Therapy, 2018, 31, e12739.	0.8	1
78	LB1509 Anti-desmoglein levels & response to the BTK inhibitor PRN1008 in pemphigus. Journal of Investigative Dermatology, 2018, 138, B7.	0.3	1
79	Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis. Case Reports in Dermatological Medicine, 2019, 2019, 1-3.	0.1	1
80	Nonâ€endemic erythrodermic pemphigus foliaceus: a case with delayed diagnosis and response to rituximab. JDDG - Journal of the German Society of Dermatology, 2019, 17, 537-539.	0.4	1
81	Scleredema diabeticorum – A case report. Journal of Family Medicine and Primary Care, 2021, 10, 1037.	0.3	1
82	Correlation of psoriasis severity with angiographic coronary artery disease complexity: a Crossâ€Sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e372-e373.	1.3	1
83	Xanthomas. , 2015, , 1063-1069.		1
84	Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece. Dermatology Reports, 0, , .	0.4	1
85	Die Übereinstimmung verschiedener Messmethoden des Nail Psoriasis Severity Index (NAPSI) und deren Korrelation mit dem Dermatology Life Quality Index (DLQI). JDDG - Journal of the German Society of Dermatology, 2014, 12, 1051-1053.	0.4	0
86	Mycosis fungoides: the great mimicker. European Journal of Cancer, 2019, 119, S15.	1.3	0
87	Pityriasis lichenoides in patients with mycosis fungoides: our experience. European Journal of Cancer, 2019, 119, S17.	1.3	0
88	Quality of life in Greek patients with mycosis fungoides: a cross-sectional study. European Journal of Cancer, 2019, 119, S40.	1.3	0
89	Cutaneous lymphoid hyperplasia: clinical course and disease outcome in a case series. European Journal of Cancer, 2019, 119, S22.	1.3	0
90	398 "Correlation of the severity of psoriasis with the complexity of coronary heart disease. Observation study with retrospective data evaluation― Journal of Investigative Dermatology, 2019, 139, S283.	0.3	0

#	Article	IF	CITATIONS
91	Nichtendemischer erythrodermischer Pemphigus foliaceus: Ein Fall mit verzögerter Diagnose und Response auf Rituximab. JDDG - Journal of the German Society of Dermatology, 2019, 17, 537-539.	0.4	O
92	Circulating Levels of Osteopontin in Patients With Psoriasis: A Systematic Review and Meta-Analysis. Journal of Psoriasis and Psoriatic Arthritis, 2019, 4, 15-21.	0.3	0
93	Sebaceous neoplasms: Just the thin end of the wedge. Clinical Case Reports (discontinued), 2020, 8, 393-395.	0.2	0
94	The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides. European Journal of Cancer, 2021, 156, S52-S53.	1.3	0
95	Evaluation of mir-146a and mir-155 plasma expression levels in patients with mycosis fungoides and detection of single nucleotide polymorphisms in their sequence. European Journal of Cancer, 2021, 156, S39.	1.3	0
96	Real world data shows that chlormethine gel is efficient and safe in mycosis fungoides skin lesions. European Journal of Cancer, 2021, 156, S16.	1.3	0